CHK1 Inhibitor Design for Selective Cancer Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using DNA damaging cytotoxic chemotherapeutic agents and ionizing radiation lack tumor cell specificity, leading to toxicity in normal tissues and resistance mechanisms that limit their effectiveness, as they activate cell cycle checkpoints that protect genomic integrity and are essential for both normal and cancer cells.
Innovation Solution
Development of 1H-pyrrolo[2,3-b]pyridine derivatives as CHK1 inhibitors to selectively target and inhibit the cell cycle checkpoints in cancer cells, particularly those with defective p53 pathways, enhancing the lethality of DNA-damaging chemotherapy without increasing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA damaging cytotoxic chemotherapeutic agents are administered at maximum tolerated dose, then therapeutic effectiveness is improved, but toxicity to normal tissue increases
Solution Approach 1:
The patent applies local quality by designing CHK1 inhibitors with specific molecular structures that selectively target cancer cells with defective p53 pathways while sparing normal cells with functional p53 pathways. The compounds exhibit differential toxicity based on the cellular context (p53 status), allowing localized therapeutic effect on tumor cells without systemic toxicity to normal tissues.
Solution Approach 2:
The patent utilizes parameter changes by modifying the molecular structure of CHK1 inhibitors to optimize their selectivity profile. By varying structural parameters (substituents on the pyrrolopyridine core), the compounds achieve enhanced selectivity for p53-deficient cells, changing the therapeutic parameter from non-specific DNA damage to specific checkpoint inhibition in vulnerable cells.
2Productivity
If DNA damaging agents are used to treat cancer, then tumor cell death is increased, but resistance mechanisms develop that limit long-term effectiveness
Solution Approach 1:
The patent applies preliminary action by using CHK1 inhibitors to pre-emptively block the DNA damage response pathway before chemotherapy administration. By inhibiting CHK1 in advance, the patent prevents cancer cells from mounting a protective response to DNA damage, thereby eliminating resistance mechanisms that would otherwise limit long-term therapeutic effectiveness.
Solution Approach 2:
The patent introduces CHK1 inhibitors as an intermediary agent that mediates between the chemotherapy drug and the cancer cell's DNA repair machinery. The inhibitor blocks the intermediary signaling pathway (CHK1-mediated cell cycle checkpoint), preventing the cell from recovering from DNA damage and thereby ensuring sustained therapeutic effectiveness.
3Stability of the object's composition
If cell cycle checkpoints are activated to protect genomic integrity, then normal cell function is maintained, but cancer cell proliferation is protected
Solution Approach 1:
The patent applies inversion by reversing the normal protective function of cell cycle checkpoints. Instead of allowing checkpoints to protect cancer cells (as they do in normal cells), the CHK1 inhibitor blocks the checkpoint pathway, inverting its protective role into a lethal effect for cancer cells with defective p53 pathways, thereby eliminating the protection while maintaining genomic integrity in normal cells.
Data Source
AI summary
The inventions relates to compounds of (I) and therapeutic uses thereof : (I) The terms Z, Y, and R1 are as defined in the claims.